FAIRFIELD, N.J., Dec. 15 /PRNewswire-FirstCall/ -- Bradley Pharmaceuticals, Inc. today announced the addition of two highly experienced executives: William Renzo, Vice President, Trade/Managed Care Relations for Bradley Pharmaceuticals and David Argento, Director, Trade Relations for Bradley Pharmaceuticals.
As Vice President of Trade/Managed Care Relations, William Renzo will have the overall responsibility for the Trade Relations, Managed Care and International Marketing departments and will interact heavily with Bradley’s Financial Department Staff. Mr. Renzo, as Vice President of Managed Care and Trade Relations, will also join TEAM BRADLEY headed by the Company’s Chairman of the Board, President and CEO. TEAM BRADLEY oversees the management of the entire Company. The other members of TEAM BRADLEY are the following Vice Presidents: Chief Financial Officer, Sales & Marketing, Chief Scientific Officer, and Corporate Development.
David Argento, under the direction of Mr. Renzo, will manage all Bradley interactions with drug distribution wholesalers and chains. He will also function as the lead contact for wholesaler and chain relationships, in charge of executing and managing Bradley’s commercial contracts.
Mr. Renzo brings to Bradley over 18 years of pharmaceutical and management experience. He began with Pfizer, Inc, as Director, Division Operations, where he worked in key locations. After several years of intensive training, he became the General Manager for the Puerto Rican and Caribbean territories for Johnson & Johnson. Mr. Renzo was instrumental in building a Sales and Marketing organization from the ground up, including the formation of functional groups such as Operations, Finance, Human Resources, Trade Relations and Marketing.
Mr. Argento brings to Bradley over 20 years of pharmaceutical and management experience. His most recent employment was with Bayer Healthcare where he held the position of Director of Trade. Mr. Argento led a team of 63 with 7 direct reports, 17 national and regional account managers and 40 retail specialty representatives. His leadership invigorated the department, increased accountability and improved results.
President and CEO, Daniel Glassman, stated, “The addition of these two highly experienced trade executives will serve to focus our distribution efforts, with increased checks and balances, and strengthen the overall infrastructure of the Company. These professionals will be responsible to direct the operation of a separate department within the Bradley corporate structure for facilitating the increased development and effective execution of our Trade, Managed Care and International relationships with the many trade distribution companies with which we have both ongoing and future connections.”
Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty pharmaceutical company and markets to niche physician specialties in the U.S. and 38 international markets. Bradley’s success is based on the strategy of Acquire, Enhance and Grow. Bradley Acquires non-strategic brands, Enhances these brands with line extensions and improved formulations and Grows the products through promotion, advertising and selling activities to optimize life cycle management. Bradley Pharmaceuticals is comprised of Doak Dermatologics, specializing in topical therapies for dermatology and podiatry, and Kenwood Therapeutics, providing gastroenterology, respiratory and other internal medicine brands
Important announcement:
Daniel Glassman will present at the Raymond James & Associates 27th Annual Institutional Investors Conference, Hyatt Regency Grand Cypress in Orlando, FL, March 5-8th, 2006.
Daniel Glassman will present at the Banc of America Securities LLC, Health Care Conference 2006, to be held at The Four Seasons Hotel in Las Vegas, NV, May 16-18th, 2006.
Please visit Bradley Pharmaceuticals web site at: www.bradpharm.com
Bradley Pharmaceuticals common stock is listed on the NYSE under the symbol BDY.
Bradley Pharmaceuticals, Inc.
CONTACT: Anthony Griffo, Investor Relations, Bradley Pharmaceuticals,Inc., +1-973-882-1505, ext. 313
Web site: http://www.bradpharm.com//
